Potential Benefits of Sequential Inhibitor-Mutagen Treatments of RNA Virus Infections
Open Access
- 13 November 2009
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS Pathogens
- Vol. 5 (11) , e1000658
Abstract
Lethal mutagenesis is an antiviral strategy consisting of virus extinction associated with enhanced mutagenesis. The use of non-mutagenic antiviral inhibitors has faced the problem of selection of inhibitor-resistant virus mutants. Quasispecies dynamics predicts, and clinical results have confirmed, that combination therapy has an advantage over monotherapy to delay or prevent selection of inhibitor-escape mutants. Using ribavirin-mediated mutagenesis of foot-and-mouth disease virus (FMDV), here we show that, contrary to expectations, sequential administration of the antiviral inhibitor guanidine (GU) first, followed by ribavirin, is more effective than combination therapy with the two drugs, or than either drug used individually. Coelectroporation experiments suggest that limited inhibition of replication of interfering mutants by GU may contribute to the benefits of the sequential treatment. In lethal mutagenesis, a sequential inhibitor-mutagen treatment can be more effective than the corresponding combination treatment to drive a virus towards extinction. Such an advantage is also supported by a theoretical model for the evolution of a viral population under the action of increased mutagenesis in the presence of an inhibitor of viral replication. The model suggests that benefits of the sequential treatment are due to the involvement of a mutagenic agent, and to competition for susceptible cells exerted by the mutant spectrum. The results may impact lethal mutagenesis-based protocols, as well as current antiviral therapies involving ribavirin. RNA viruses are associated with many important human and animal diseases such as AIDS, influenza, hemorrhagic fevers and several forms of hepatitis. RNA viruses mutate at very high rates and, therefore, can adapt easily to environmental changes. Viral mutants resistant to antiviral inhibitors are readily selected, resulting in treatment failure. The simultaneous administration of three or more inhibitors is a means to prevent or delay selection of resistant mutants. A new antiviral strategy termed lethal mutagenesis is presently under investigation. It consists of the administration of mutagenic agents to elevate the mutation rate of the virus above the maximum level compatible with virus infectivity, without mutagenizing the host cells. Since low amounts of virus are extinguished more easily, the combination of a mutagen and inhibitor was more efficient than a mutagen alone in driving virus to extinction. Here we show that foot-and-mouth disease virus replicating in cell culture can be extinguished more easily when the inhibitor guanidine is administered first, followed by the mutagenic agent ribavirin, than when both drugs are administered simultaneously. Interfering mutants that contribute to extinction were active in the presence of ribavirin but not in the presence of guanidine. This observation provides a mechanism for the advantage of the sequential versus the combination treatment. This unexpected effectiveness of a sequential treatment is supported by a theoretical model of virus evolution in the presence of the inhibitor and the mutagen. The results can have an application for future lethal mutagenesis protocols and for current antiviral treatments that involve the antiviral agent ribavirin when it acts as a mutagen.Keywords
This publication has 104 references indexed in Scilit:
- Effect of Ribavirin on the Mutation Rate and Spectrum of Hepatitis C Virus In VivoJournal of Virology, 2009
- Counteracting Quasispecies Adaptability: Extinction of a Ribavirin-Resistant Virus Mutant by an Alternative Mutagenic TreatmentPLOS ONE, 2009
- Lethal Mutagenesis of Picornaviruses with N-6-Modified Purine Nucleoside AnaloguesAntimicrobial Agents and Chemotherapy, 2008
- Lethal Mutagenesis of Poliovirus Mediated by a Mutagenic Pyrimidine AnalogueJournal of Virology, 2007
- Synthesis of a Universal 5‐Nitroindole Ribonucleotide and Incorporation into RNA by a Viral RNA‐Dependent RNA PolymeraseChemBioChem, 2007
- Analysis of Ribavirin Mutagenicity in Human Hepatitis C Virus InfectionJournal of Virology, 2007
- Collective properties of evolving molecular quasispeciesBMC Ecology and Evolution, 2007
- Insights into RNA Virus Mutant Spectrum and Lethal Mutagenesis Events: Replicative Interference and Complementation by Multiple Point MutantsJournal of Molecular Biology, 2007
- Foot-and-Mouth Disease Virus Mutant with Decreased Sensitivity to Ribavirin: Implications for Error CatastropheJournal of Virology, 2007
- Synthesis and Antiviral Activity of 5-Substituted Cytidine Analogues: Identification of a Potent Inhibitor of Viral RNA-Dependent RNA PolymerasesJournal of Medicinal Chemistry, 2006